Chemoprevention of Cancer of the Respiratory Tract by Agents Delivered by Aerosol

Applications to Glucocorticoids and 5-Fluorouracil
  • Timothy S. Wiedmann
  • Lee W. Wattenberg
Part of the Cancer Drug Discovery and Development book series (CDD&D)


Aerosol administration of chemopreventive agents has distinct advantages in chemoprevention of respiratory tract carcinogenesis. First, the agent is delivered directly to the target tissue. Another major advantage is the favorable ratio of agent concentration reaching the respiratory tract as compared to that reaching the systemic tissues. At the same dose, the initial agent concentration in the lung will be approx 30x greater when the compounds are given by aerosol than when administered orally (1). This difference is further enhanced for agents that undergo metabolism in systemic tissues (2).


Chemopreventive Agent Mass Median Aerodynamic Diameter Aerosol Delivery Aerosol Cloud Ultrasonic Atomization 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sharma S, White D, Imondi AR, et al. Development of inhalational agents for oncologic use. J Clin Oncol 2001;19:1839–1847.PubMedGoogle Scholar
  2. 2.
    Edsbacker S. Uptake, retention, and biotransformation of corticosteroids in the lung and airways. Schleimer RP, O’Byrne PM, Szefler SJ, Brattsand R, eds. in: Inhaled Steroids in Asthma: Marcel Dekker, Inc., New York, 2002, pp. 213–246.Google Scholar
  3. 3.
    Everard ML. Aerosol therapy past, present, and future: a clinician’s perspective. Respir Care 2000;45:769–776.PubMedGoogle Scholar
  4. 4.
    Hickey AJ, Garcia-Contreras L. Immunological and toxicological implications of short-term studies in animals of pharmaceutical aerosol delivery to the lungs: relevance to humans. Crit Rev Ther Drug Carrier Syst 2001;18:387–431.PubMedCrossRefGoogle Scholar
  5. 5.
    Gonda I. The ascent of pulmonary drug delivery. J Pharm Sci 2000;89:940–945.PubMedCrossRefGoogle Scholar
  6. 6.
    Dalby RN, Hickey AJ, Tiano SL. Medical devices for the delivery of therapeutic aerosols to the lungs, in Inhalation Aerosols. Physical and Biological Basis for Therapy. Hickey Ai, ed. Marcel Dekker, Inc., New York, Inc., 1996,pp.441–473.Google Scholar
  7. 7.
    Guidelines for the Diagnosis and Management of Asthma: Expert Panel Report. Bethesda, MD National Heart, Lung and Blood Institute, 1997, pp.57–79.Google Scholar
  8. 8.
    Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1997;332:868–875.Google Scholar
  9. 9.
    Pederson S, Hansen OR. Budesonide treatment of moderate and severe asthma in children: a dose-response study. J Allergy Clin Immunol 1994; 29–33.Google Scholar
  10. 10.
    Wattenberg LW, Wiedmann TS, Estensen RD, et al. Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol. Carcinogenesis 2000;21:179–182.PubMedCrossRefGoogle Scholar
  11. 11.
    Bolt, RJ, van Weissenbruch MM, Lafeber HN, Delemarrevan de Waal HA. Glucocorticoids and lung development in the fetus and preterm infant. Pediatr Pulmonol 2001;32:76–91.PubMedCrossRefGoogle Scholar
  12. 12.
    Pierce GB, Speers WC. Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res 1988;48:1996–2004.PubMedGoogle Scholar
  13. 13.
    Marks PA, Rifkind RA. Differentiating agents in cancer therapy, in Cancer Chemotherapy and Biological Response Modifers Annual 12. Pinedo HM, Longo DL, Chabner BA, eds. Elsevier Science Publishers, New York, 1991, pp.291–305.Google Scholar
  14. 14.
    Conley BA, Egorin MJ, Tait N, et al. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. Clin Canc Res 1998;4:629–634.Google Scholar
  15. 15.
    Cheson BD, Jasperse DM, Chun HG, Friedman MA. Differentiating agents in the treatment of human malignancies. Cancer Treat Rev 1986;13:129–145.PubMedCrossRefGoogle Scholar
  16. 16.
    Mintz B, Illmensee K. Normal genetically mosaic mice produced from malignant teratocarcinoma cell. Proc Natl Acad Sci USA 1975;72:3585–3589.PubMedCrossRefGoogle Scholar
  17. 17.
    Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980;20:85–93.PubMedCrossRefGoogle Scholar
  18. 18.
    Sporn MB, Roberts AB. Role of retinoids in differentiation and carcinogenesis. Cancer Res 1983;43:3034–3040.PubMedGoogle Scholar
  19. 19.
    Estensen RD, Wattenberg LW. Studies of chemopreventive effects of myo-inositol on benzopyrene-induced neoplasia of the lung and forestomach of female A/J mice. Carcinogenesis 1993;14:1975–1977.PubMedCrossRefGoogle Scholar
  20. 20.
    Wattenberg LW. Chalcones, myo-inositol and other novel inhibitors of pulmonary carcinogenesis. J Cell Biochem Suppl 1995;22:1162–1168.Google Scholar
  21. 21.
    Wattenberg LW, Estensen RD. Chemopreventive effects of myo-inositol and dexamethasone on benzo[a]pyrene and 4(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone-induced pulmonary carcinogenesis in female A/J mice. Cancer Res 1996;56:5132–5135.PubMedGoogle Scholar
  22. 22.
    Belman S, Troll W. The inhibition of croton oil-promoted mouse skin tumorigenesis by steroid hormones. Cancer Res 1972;32:450–454.PubMedGoogle Scholar
  23. 23.
    Verma AK, Garcia CT, Ashendel CL, Boutwell RK. Inhibition of 7-bromomethylbenz[a]anthracene-promoted mouse skin tumor formation by retinoic acid and dexamethasone. Cancer Res 1983;43:3045–3049.PubMedGoogle Scholar
  24. 24.
    Shimkin MB. Pulmonary tumors in experimental animals. Adv Cancer Res 1955;3:223–267.PubMedCrossRefGoogle Scholar
  25. 25.
    Pederson S, Hansen OR. Budesonide treatment of moderate and severe asthma in children: a dose-response study. J Allergy Clin Immunol 1994;95:29–33.CrossRefGoogle Scholar
  26. 26.
    Wattenberg LW, Estensen RD. Studies of chemopreventive effects of budesonide on benzopyrene induced neoplasia of the lung in female A/J mice. Carcinogenesis (Lond) 1997;18:2015–2017.CrossRefGoogle Scholar
  27. 27.
    Ullah A, Shamsuddin AM. Dose-dependent inhibition of large intestinal cancer by inositol hexaphosphate in F344 rats. Carcinogenesis 1990;11:2219–2222.PubMedCrossRefGoogle Scholar
  28. 28.
    Hallman M, Bry K, Hoppu K, Lappi M, Pohjavuori M. Inositol supplementation in premature infants with respiratory distress syndrome. N Engl J Med 1992;326:1233–1239.PubMedCrossRefGoogle Scholar
  29. 29.
    Jyonouchi H., Sun S, Iijima K, et al. Effects of anti-7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene on human small airway epithelial cells and the protective effects of myo-inositol. Carcinogenesis 1999;20:139–145.PubMedCrossRefGoogle Scholar
  30. 30.
    Yorek MA, Dunlap JA, Lowe WL Jr. Osmotic regulation of the NA+/myo-inositol cotransporter and postinduction normalization. Kidney Int 1999;55:215–224.PubMedCrossRefGoogle Scholar
  31. 31.
    Dillaha CJ, Jansen GT, Honeycutt WM, Holt GA. Further studies with topical 5-fluorouracil. Arch Dermatol 1965;92:410–417.PubMedCrossRefGoogle Scholar
  32. 32.
    Williams AC, Klein E. Experiences with local chemotherapy and immunotherapy in premalignant and malignant skin lesions. Cancer 1970;24(2):450–462.CrossRefGoogle Scholar
  33. 33.
    Olson PR, Wattenberg LW. Inhibition by 5-fluorouracil of the early stages of chemical carcinogenesis in mouse skin (34054). Proc Soc Exp Biol Med 1969;131:1135–1137.PubMedGoogle Scholar
  34. 34.
    Hugosson J, Bergdahl S, Carlsson G, et al. Effects of intravesical instillation of 5-fluorouracil and interferon in patients with recurrent superficial urinary bladder carcinoma. Scand J Urol Nephrol 1997;31:343–347.PubMedCrossRefGoogle Scholar
  35. 35.
    Tatsumura T, Koyama S, Tsujimoto M, et al. Further study of nebulisation chemotherapy; a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical. Br J Cancer 1993;68:1146–1149.PubMedCrossRefGoogle Scholar
  36. 36.
    Wiedmann TS, Wattenberg LW. Chemoprevention of infiltrating squamous cell carcinoma of the upper respiratory tract of the Syrian golden hamster by 5-fluorouacil delivered by aerosol. Proc Am Assoc Cancer Res 2002;43:307, abst no 1526.Google Scholar
  37. 37.
    Wattenberg LW, Wiedmann TS, Estensen RD, et al. Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res 1997;57:5489–5492.PubMedGoogle Scholar
  38. 38.
    Mygind N. Upper airway: structure, function and therapy, in Aerosols in Medicine. Moren F, Newhouse M, Dolovich MB, eds. Elsevier, New York, 1985, pp.1–20.Google Scholar
  39. 39.
    Hochhaus G, Mollmann H, Derendorf H, Gonzalez-Rothi RJ. Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model. J Clin Pharmacol 1997;37:881–892.PubMedCrossRefGoogle Scholar
  40. 40.
    Byron PR. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci 1986;75:433–438.PubMedCrossRefGoogle Scholar
  41. 41.
    Chonda I. Drugs administered directly into the respiratory tract; modeling of the duration of effective drug levels. J Pharm Sci 1988;77:340–346.CrossRefGoogle Scholar
  42. 42.
    Collins JM. Pharmacological rationale for regional drug delivery. J Clin Oncol 1984;2:498–504.PubMedGoogle Scholar
  43. 43.
    Mygind N, Dahl R. Anatomy, physiology and function of the nasal cavities in health and disease. Adv Drug Delivery Rev 1998;29:3–12.CrossRefGoogle Scholar
  44. 44.
    Kreyling WG, Scheuch G. Clearance of particles deposited in the lungs, in Lung Biology in Health and Disease, Vol. 143. Gehr P, Heyder J, eds. Marcel Dekker, Inc., New York, 2000, pp. 323–376.Google Scholar
  45. 45.
    Gehr P, Hof VI, Geiser M, Schurch S. The fate of particles deposited in the intrapulmonary conducting airways. J Aerosol Med 1991;4:349–361.CrossRefGoogle Scholar
  46. 46.
    Girod S, Zahm J-M, Plotkowski C, et al. Role of the physicochemical properties of mucus in the protection of the respiratory epithelium. Eur Respir J 1992;5:477–487.PubMedGoogle Scholar
  47. 47.
    Geiser M, Hof VI, Gehr P, Schurch S. Structural and interfacial aspects of particle retention, in Lung Biology in Health and Disease, Vol. 143. Gehr P, Heyder J, eds. Marcel Dekker, Inc., New York, 2000, pp. 291–321.Google Scholar
  48. 48.
    Ferin J, Oberdorster G, Penney DP. Pulmonary retention of ultrafine and fine particles in rats. Am J Respir Cell Mol Biol 1992;6:535–542.PubMedGoogle Scholar
  49. 49.
    Heyder J, Gebhart J, Rudolf G, et al. Deposition of particles in the human respiratory tract in the size range 0.005–15 µm. J Aerosol Sci 1986;17:811–825.CrossRefGoogle Scholar
  50. 50.
    Raabe OG, Al-Bayati MA, Teague SV, Rasolt A. Regional deposition of inhaled monodispersed coarse and fine aerosol particles in small laboratory animals. Ann Occup Hyg 1988;32:53–65.CrossRefGoogle Scholar
  51. 51.
    Swift DL. Use of mathematical aerosol deposition models in predicting the distribution of inhaled therapeutic aerosols, in Inhalation aerosols. Physical and biological basis for therapy, in. Lung Biology in Health and Disease, Vol 94, Hickey AJ, ed. Marcel Dekker, Inc., New York, 1996; pp. 51–81.Google Scholar
  52. 52.
    Edsbacker S, Szefler SJ, Glucocorticoid pharmacokinetics, in Inhaled Glucocorticosteroids in Asthma. Schleima RP, Busse WW, O’Byrne PM eds. Marcel Dekker, Inc., NY, 1997; pp.381–492.Google Scholar
  53. 53.
    Hickey AJ, Concessio NM. Descriptors of irregular particle morphology and powder properties. Adv Drug Delivery Rev 1997;26:29–40.CrossRefGoogle Scholar
  54. 54.
    Washington C. Particle size analysis in inhalation therapy, in Metered Dose Inhaler Technology. Purewal TS, Grant DJW, eds. Interpharm Press, Inc., Buffalo Grove, IL, 1998, 117–146.Google Scholar
  55. 55.
    Phillips PR, Gonda I. Droplets produced by medical nebulizers. Some factors affecting their size and solute concentration. Chest 1990;97:1327–1332.CrossRefGoogle Scholar
  56. 56.
    Guyton AC. Measurement of the respiratory volumes of laboratory animals. Am J Physiol 1947;150:7–77.Google Scholar
  57. 57.
    Wiedmann TS, Ravichandran A. Ultrasonic nebulization system for respiratory drug delivery. Pharm Dev Technol 2001;6:83–90.PubMedCrossRefGoogle Scholar
  58. 58.
    Pham S, Wiedmann TS. A novel method for the rapid screening of poorly water soluble drugs for respiratory delivery. Pharm Res 1999;16:1857–1863.PubMedCrossRefGoogle Scholar
  59. 59.
    Niven RW. Atomization and nebulizers in inhalation aerosols, in Physical and Biological Basis for Therapy. Hickey AJ, ed. Marcel Dekker, Inc., New York, 1996, pp. 273–312.Google Scholar
  60. 60.
    Greenspan BJ. Ultrasonic and electrohydrodynamic methods for aerosol generation, in Physical and Biological Basis for Therapy. Hickey AJ, ed. Marcel Dekker, Inc., New York,1996, pp.313–35.Google Scholar
  61. 61.
    Lang RJ. Ultrasonic atomization of liquids. JAcoust Soc Am 1962;34:6–8.CrossRefGoogle Scholar
  62. 62.
    Taylor KMG, McCallion ONM. Ultrasonic nebulizers for pulmonary drug delivery. Int J Pharm 1997;153:93–104.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Timothy S. Wiedmann
  • Lee W. Wattenberg

There are no affiliations available

Personalised recommendations